Madrigal Pharmaceuticals Overview
Madrigal Pharmaceuticals Target Price
Analysts' 12-month price predictions for MDGL.
Share Price
$290.96
Average Target Price
$420.00
44.3% upside
44.3% upside1 analysts in the last 4 months
High: $420 | Low: $420
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-05-02 | Canaccord GenuityEdward Nash | $420 | 44.3% upside |  |
| 2024-05-29 | Piper SandlerYasmeen Rahimi | $336 | 15.5% upside | |
| 2024-05-09 | H.C. WainwrightEd Acre | $390 | 34% upside | |
| 2024-03-19 | Evercore ISILiisa Bayko | $405 | 39.2% upside | |
| 2024-03-15 | UBSEliana Merle | $410 | 40.9% upside | |
| 2024-03-15 | JefferiesAkash Tewari | $400 | 37.5% upside | |
| 2024-03-15 | H.C. WainwrightEd Acre | $425 | 46.1% upside | |
| 2024-03-15 | JMP SecuritiesJonathan Wolleben | $397 | 36.4% upside | |
| 2024-03-15 | B.Riley FinancialMayank Mamtani | $270 |  7.2% downside | |
| 2023-01-05 | JMP Securities | $390 | 34% upside | |
| 2022-12-21 | UBS | $337 | 15.8% upside | |
| 2022-12-20 | H.C. Wainwright | $225 | 22.7% downside | |
| 2022-12-20 | Oppenheimer | $250 | 14.1% downside | |
| 2022-12-20 | Goldman Sachs | $375 | 28.9% upside | |
| 2022-12-20 | JMP Securities | $312 | 7.2% upside | |
| 2022-12-20 | Leerink Partners | $315 | 8.3% upside | |
| 2021-08-06 | BMO CapitalMatthew Luchini | $111 | 61.9% downside | |
| 2021-05-20 | Goldman SachsAndrea Tan | $195 | 33% downside | |
| 2021-05-06 | Wells FargoDerek Archila | $130 | 55.3% downside | |